What are other Names of this Test? (Equivalent Terms)
- Gene Mutation Analysis for Synovial Sarcoma
- Molecular Testing for SS
- Test for Molecular Diagnosis of Synovial Sarcoma
What is Molecular Testing for Synovial Sarcoma? (Background Information)
- Molecular Testing for Synovial Sarcoma is a genetic test that is helpful in aiding a diagnosis of synovial sarcoma. The lab test results may also be subsequently useful in taking appropriate treatment decisions
- A synovial sarcoma (SS) is a type of malignant tumor of the connective tissue, involving the tendon sheath and synovial cells of the joints
- Synovium refers to the lubricating layer found in the joints (knee, elbow); synovium is responsible for making the synovial fluid. However, a synovial sarcoma is not confined to the joint locations alone; but, may occur in soft tissues all over the body
- Individuals, below the age of 35 years, are commonly affected by this tumor. The main sites of SS are the lower limb joints, followed by the head and neck region
The cause of synovial sarcoma is due to genetic mutations. Currently, studies indicate defects in the following fusion genes:
Note: All gene defects noted above cause the chromosomal translocation abnormality namely t(X;18)(p11;q11).
These genetic abnormalities can be detected using molecular studies, which may play a significant role in identifying the tumor type, and in some cases, helping the healthcare provider take appropriate treatment decisions.
The molecular testing, in general, can be performed using a variety of methods. Some of these methods include:
- In situ hybridization technique, such as fluorescence in situ hybridization (FISH)
- Immunohistochemistry (IHC)
- Next-generation sequencing (NGS)
- Polymerase chain reaction (PCR)
- Comparative genomic hybridization (CGH)
- Karyotyping including spectral karyotyping
- mRNA analysis
- Tissue microarrays (TMAs)
- Southern blot test
- Northern blot test
- Western blot test
- Eastern blot test
The methodology used for synovial sarcoma may vary from one laboratory to another.
Note: Molecular testing has limitations due to the molecular method and genetic mutational abnormalities being tested. This can affect the results on a case-by-case basis. Consultation with your healthcare provider will help in determining the right test and right molecular method, based on individual circumstances.
What are the Clinical Indications for performing the Molecular Testing for Synovial Sarcoma Test?
Molecular Testing for Synovial Sarcoma is undertaken in the following situations:
- To assist (and in some cases, confirm) the initial diagnosis of synovial sarcoma
- To distinguish other tumors/conditions that have similar histological features, when examined by a pathologist under the microscope
- To help in determining treatment options
- To confirm recurrence of the tumor: Tumor recurrence can either be at the original tumor site, or at a distant location (away from the initial site)
How is the Specimen Collected for Molecular Testing for Synovial Sarcoma?
Following is the specimen collection process for Molecular Testing for Synovial Sarcoma:
The specimen sample requirements may vary from lab to lab. Hence, it is important to contact the testing lab for exact specimen requirements, before initiating the testing process.
- Sample required:
- Fresh tumor tissue during biopsy
- Formalin-fixed paraffin-embedded solid tumor tissue (FFPE tumor tissue), often referred to as paraffin block of the tumor
- Unstained tissue slides
- Process of obtaining the sample: As outlined by the laboratory testing facility
- Preparation required: As outlined by the laboratory testing facility
- Depending on the location of testing, it may take up to 2 weeks’ turnaround time, to obtain the test results
- Occasionally, additional samples may be required to either repeat the test or to perform follow-up testing
- Many hospitals preserve the paraffin blocks for at least 7 years. In general, older paraffin blocks (over 5 years) may affect the detection of specific mutations, due to degradation of the tumor specimen over time
Cost of Molecular Testing for Synovial Sarcoma:
- The cost of the test procedure depends on a variety of factors, such as the type of your health insurance, annual deductibles, co-pay requirements, out-of-network and in-network of your healthcare providers and healthcare facilities
- In many cases, an estimate may be provided before the test is conducted. The final amount may depend upon the findings during the test procedure and post-operative care that is necessary (if any)
What is the Significance of the Molecular Testing for Synovial Sarcoma Result?
The significance of Molecular Testing for Synovial Sarcoma is explained:
- Presence of a positive test result helps aid, and in some cases, confirm the diagnosis of synovial sarcoma
- The result can help exclude other tumors with similar histological features
- It can help determine the prognosis of the patient
- In some cases, the test results may help in taking treatment decisions
The laboratory test results are NOT to be interpreted as results of a "stand-alone" test. The test results have to be interpreted after correlating with suitable clinical findings and additional supplemental tests/information. Your healthcare providers will explain the meaning of your tests results, based on the overall clinical scenario.
Additional and Relevant Useful Information for Molecular Testing for Synovial Sarcoma:
- Many laboratories may not have the capability to perform this test. Only highly-specialized labs with advanced facilities and testing procedures may perform this test
- Additional mutations are still being discovered in many of these tumors. This may further contribute towards tumor diagnosis and treatment. Please consult with your healthcare provider for any information updates
Certain medications that you may be currently taking may influence the outcome of the test. Hence, it is important to inform your healthcare provider of the complete list of medications (including any herbal supplements) you are currently taking. This will help the healthcare provider interpret your test results more accurately and avoid unnecessary chances of a misdiagnosis.
What are some Useful Resources for Additional Information?
The following DoveMed website link is a useful resource for additional information:
Please visit our Laboratory Procedures Center for more physician-approved health information:
References and Information Sources used for the Article:
https://ghr.nlm.nih.gov/primer/testing/genetictesting (accessed on 02/17/2017)
https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5806a1.htm (accessed on 02/17/2017)
http://www.nature.com/gim/journal/v10/n5/full/gim200852a.html (accessed on 02/17/2017)
http://pediatrics.aappublications.org/content/106/6/1494 (accessed on 02/17/2017)
https://rarediseases.info.nih.gov/diseases/7721/synovial-sarcoma/cases/31407 (accessed on 02/17/2017)
http://atlasgeneticsoncology.org/Tumors/SynovSarcID5044.html (accessed on 02/17/2017)
http://www.cancerindex.org/geneweb/X200302.htm (accessed on 02/17/2017)
Helpful Peer-Reviewed Medical Articles:
Carrano, A. V., et al. Measurement and purification of human chromosomes by flow cytometry and sorting. Proceedings of the National Academy of Sciences 76, 1382–1384 (1979)
Drets, M. E., & Shaw, M. W. Specific banding patterns of human chromosomes. Proceedings of the National Academy of Sciences 68, 2073–2077 (1971)
Druker, B. J. Perspectives on the development of a molecularly targeted agent. Cancer Cell 1, 31–36 (2002)
Parra, I., & Windle, B. High resolution visual mapping of stretched DNA by fluorescent hybridization. Nature Genetics 5, 17–21 (1993) doi:10.1038/ng0993-17
Pinkel, D., et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nature Genetics 20, 207–211 (1998) doi:10.1038/2524
Speicher, M. R., et al. Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nature Genetics 12, 368–375 (1996) doi:10.1038/ng0496-368
O'sullivan, P. J., Harris, A. C., & Munk, P. L. (2014). Radiological features of synovial cell sarcoma. The British journal of radiology.
Kadoch, C., & Crabtree, G. R. (2013). Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell, 153(1), 71-85.
Naka, N., Takenaka, S., Araki, N., Miwa, T., Hashimoto, N., Yoshioka, K., ... & Ueda, T. (2010). Synovial sarcoma is a stem cell malignancy. Stem cells, 28(7), 1119-1131.
Krieg, A. H., Hefti, F., Speth, B. M., Jundt, G., Guillou, L., Exner, U. G., ... & Kaelin, A. (2010). Synovial sarcomas usually metastasize after> 5 years: a multicenter retrospective analysis with minimum follow-up of 10 years for survivors. Annals of oncology, mdq394.
Lagarde, P., Przybyl, J., Brulard, C., Pérot, G., Pierron, G., Delattre, O., ... & Neuville, A. (2013). Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. Journal of Clinical Oncology, 31(5), 608-615.
Ritter, G. (2013). A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma. Sarcoma, 2013.
Brennan, B., Stevens, M., Kelsey, A., & Stiller, C. A. (2010). Synovial sarcoma in childhood and adolescence: a retrospective series of 77 patients registered by the Children's Cancer and Leukaemia Group between 1991 and 2006. Pediatric blood & cancer, 55(1), 85-90.
Lai, J. P., Robbins, P. F., Raffeld, M., Aung, P. P., Tsokos, M., Rosenberg, S. A., ... & Lee, C. C. R. (2012). NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis. Modern Pathology, 25(6), 854-858.
Michels, S., Trautmann, M., Sievers, E., Kindler, D., Huss, S., Renner, M., ... & Wurst, P. (2013). SRC signaling is crucial in the growth of synovial sarcoma cells. Cancer research, 73(8), 2518-2528.
Bakri, A., Shinagare, A. B., Krajewski, K. M., Howard, S. A., Jagannathan, J. P., Hornick, J. L., & Ramaiya, N. H. (2012). Synovial sarcoma: imaging features of common and uncommon primary sites, metastatic patterns, and treatment response. American Journal of Roentgenology, 199(2), W208-W215.